Our Oncology Clinical Strategy is designed to transform survival
At AstraZeneca, we think differently about the underlying genetic causes of cancer. Our clinical strategy aims to transform survival by seeking to combat metastatic and resistant disease and providing options to treat early. We are defining new biomarkers and therapeutic targets that cut across multiple tumour types. We are transforming the way people with cancer are diagnosed and treated by looking in new places, beyond traditional classifications and focusing on the properties of a tumour, not just its type.
Introduction to our clinical strategy
Our clinical stratgy is designed to transform survival. We aim to combat cancer at all stages, but we know that the earlier we can detect and address cancer, the closer we may be to better outcomes.
Latest Oncology News
Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
Enhertu demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
Imfinzi and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
AstraZeneca lung and breast cancer data at WCLC and ESMO 2021 underscore ambition to revolutionise outcomes for patients
Explore our Oncology pillars
Veeva ID: Z4-34100
Date of Prep: June 2021